POLVERE, JACOPO
 Distribuzione geografica
Continente #
EU - Europa 592
NA - Nord America 189
AS - Asia 81
AF - Africa 9
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 876
Nazione #
IT - Italia 225
US - Stati Uniti d'America 183
IE - Irlanda 140
RU - Federazione Russa 66
SG - Singapore 47
FI - Finlandia 30
SE - Svezia 29
FR - Francia 25
DE - Germania 24
CN - Cina 21
GB - Regno Unito 16
CZ - Repubblica Ceca 11
NL - Olanda 8
CA - Canada 6
ES - Italia 6
ZA - Sudafrica 5
CI - Costa d'Avorio 4
IR - Iran 4
PL - Polonia 3
BO - Bolivia 2
CH - Svizzera 2
IL - Israele 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AT - Austria 1
EC - Ecuador 1
EU - Europa 1
GR - Grecia 1
HK - Hong Kong 1
IN - India 1
LT - Lituania 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
PT - Portogallo 1
RO - Romania 1
TH - Thailandia 1
TW - Taiwan 1
Totale 876
Città #
Dublin 139
Siena 64
Singapore 40
Florence 37
Ashburn 32
Chandler 30
Helsinki 28
New York 26
Shanghai 14
Princeton 11
Brno 9
Rome 9
Bacoli 6
Fremont 6
Málaga 6
Baronissi 5
Los Angeles 5
Manchester 5
Montreal 5
Munich 5
Washington 5
Abidjan 4
Agliana 4
Barolo 4
Columbus 4
Figline Valdarno 4
Frankfurt am Main 4
Lanciano 4
Poggibonsi 4
Slough 4
Vanderbijlpark 4
Chicago 3
Fairfield 3
Gdynia 3
Messina 3
Naples 3
Salerno 3
Amsterdam 2
Bitetto 2
Bonn 2
Groningen 2
Jinan 2
Lappeenranta 2
Lastra a Signa 2
London 2
Milan 2
Moscow 2
Nuremberg 2
Olomouc 2
Rogliano 2
Rosignano Marittimo 2
Southend 2
Trevi 2
Triggiano 2
Turin 2
Verona 2
Woodbridge 2
Arezzo 1
Athens 1
Auckland 1
Beijing 1
Bern 1
Boardman 1
Bologna 1
Boston 1
Cedar Knolls 1
Central 1
Chiswick 1
Clifton 1
Colle di Val d'Elsa 1
Como 1
Friesland 1
Houston 1
Islamabad 1
Johannesburg 1
La Paz 1
Lisbon 1
Mumbai 1
Oslo 1
Ottawa 1
Parma 1
Quito 1
Sacramento 1
San Francisco 1
San Miniato Basso 1
Santa Clara 1
Seravezza 1
Sesto Fiorentino 1
Shenzhen 1
Sucre 1
The Hague 1
Tirana 1
Umeå 1
Vienna 1
Zanjan 1
Zurich 1
Totale 624
Nome #
B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV 92
Comparison of Immune Responses Elicited by BNT162b2, mRNA-1273 and ChAdOx1 COVID-19 Vaccines. 85
A third dose of mRNA-1273 vaccine improves SARS-CoV-2 immunity in HCT recipients with low antibody response after 2 doses 79
Antibody response in myelofibrosis patients after three doses of mRNA SARS-CoV-2 vaccine 79
The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients 71
Evidence of SARS-Cov-2-specific memory B cells six months after vaccination with BNT162b2 mRNA vaccine 71
Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine 59
The slower antibody response in myelofibrosis patients after two doses of MRNA sars-COV-2 vaccine calls for a third dose 59
B cell response six months after SARS-CoV-2 mRNA vaccination in people living with HIV under antiretroviral therapy 58
Characterization of the humoral and B-cell spike-specific immune response after mRNA SARS-CoV-2 vaccination in healthy and fragile subjects 50
Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine 46
Persistence of spike-specific memory B cells and antibodies nine months after two doses of BNT162b2 mRNA vaccine. 35
Spike-Specific memory B cell response in hematopoietic cell transplantation recipients following multiple mRNA-1273 vaccinations: a longitudinal observational study 33
Antibody and B-cell responses in myelofibrosis patients after the third doses of mRNA SARS-CoV-2 vaccines 33
Third Sars-CoV-2 vaccine dose: B cell and antibody responses following heterologous and homologous vaccination strategies. 33
Longitudinal profiling of spike-specific antibody and B cell responses following mRNA-1273 SARS-CoV-2 vaccination in hematopoietic cell transplantation recipients 26
Predicting humoral responses to primary and booster SARS-CoV-2 mRNA vaccination in people living with HIV: a machine learning approach 11
Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant 8
Successivi booster vaccinali contro SARS-CoV-2: risposta umorale in pazienti sottoposti a trapianto di cuore o di polmone 6
Vaccinazione anti SARSCov2 in una coorte di pazienti sottoposti a trapianto di cuore o di polmone: risposta umorale a dosi booster 3
Totale 937
Categoria #
all - tutte 5.461
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.461


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202260 0 0 0 0 0 0 0 0 13 3 21 23
2022/2023242 14 23 37 16 15 26 14 22 12 11 43 9
2023/2024391 8 4 41 39 23 88 94 22 12 13 15 32
2024/2025244 46 24 96 49 29 0 0 0 0 0 0 0
Totale 937